Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Paul Krassnoff, Jerome Rotter


Bacterial typing systems developer PathoGenetix has hired Paul Krassnoff to be director of manufacturing. In this post, he will develop production and quality assurance systems for the firm's Genome Sequence Scanning System.

Krassnoff formerly was director of lab operations and manufacturing at Aushon Biosystems. He also worked at Alpo Diagnostics, Genzyme Diagnostics, BioMérieux, and Baxter-Dade. He holds a BS in chemistry from Boston University and an MS in biomedical science from Northeastern University.

Jerome Rotter has joined the faculty of the Los Angeles Biomedical Research Institute to launch the Translational Genomics and Population Sciences institute, which aims to use genomics to improve the health of the Hispanic, African-American, and Asian populations served by LA BioMed and the Harbor University of California, Los Angeles Medical Center.

Rotter was previously director of research at the Medical Genetics Institute at Cedars-Sinai Medical Center. He is also a professor of medicine, pediatrics, and human genetics at UCLA and Cedars-Sinai and he has held the board of governors' chair in medical genetics at Cedars-Sinai. He holds a BS and MD from UCLA.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.